Results 181 to 190 of about 2,816 (233)

Lutetium 177 dotatate induced acute myeloid leukemia

Leukemia & Lymphoma, 2020
Peptide Receptor Radionuclide Therapy (PRRT) is a molecular targeted therapy used to treat neuroendocrine tumors (NET).
Dilip Harindran, Vallathol, Abubacker Zakir, Ali, Neeharika, Alapati, Navya, Manasa, Prasad, Vasanth, Raghunadharao, Digumarti   +5 more
openaire   +2 more sources

Production of Lutetium-177: Process Aspects

Radiochemistry, 2019
Papers dealing with the 177Lu production technology are analyzed with the aim of evaluating the readiness of the existing processes to setting up regular large-scale production, which is the necessary condition for the progress of the market of 177Lu-based radiopharmaceuticals. This is now on the initial step of its development.
R. A. Kuznetsov, K. S. Bobrovskaya, V. V. Svetukhin, A. N. Fomin, A. V. Zhukov   +4 more
openaire   +1 more source

Theranostic Applications of Lutetium-177 in Radionuclide Therapy

Current Radiopharmaceuticals, 2015
Lutetium-177 has been widely discussed as a radioisotope of choice for targeted radionuclide therapy. The simultaneous emission of imageable gamma photons [208 keV (11%) and 113 keV (6.4%)] along with particulate β(-) emission [β(max) = 497 keV] makes it a theranostically desirable radioisotope.
Tapas, Das, Sharmila, Banerjee
openaire   +2 more sources

Lutetium-177 Labeled Bombesin Peptides for Radionuclide Therapy

Current Radiopharmaceuticals, 2015
The rare-earth radionuclides that decay by beta particle (β-) emission are considered to be ideal in the context of targeted radiotherapy. The rare-earth isotopes exist primarily in the 3+ oxidation state and are considered to be hard metal centers, requiring multidentate, hard donor ligands such as the poly(aminocarboxylates) for in vivo kinetic ...
Tamila Stott, Reynolds, Rajendra P, Bandari, Zongrun, Jiang, Charles J, Smith   +3 more
openaire   +2 more sources

Lutetium-177-PSMA bij gemetastaseerd prostaatcarcinoom

2023
Lutetium-177 coupled with a ligand for Prostate Specific Membrane Antigen ([177Lu]Lu-PSMA) is a new treatment in The Netherlands. Patients with metastasized castration resistant prostate carcinoma and progressive disease after hormonal therapy and chemotherapy, and no other regular therapeutic options, can be referred. A good clinical performance state,
van Golen, Larissa W., Vogel, Wouter, Lam, Marnix G.E.H.   +2 more
openaire   +1 more source

Maintenance Factors Affecting Increased Lutetium-177 Production

Journal of Nuclear Engineering and Radiation Science, 2021
Abstract With lutetium (Lu-177) demand forecasted to increase following the conclusion of clinical trials and product registration in key jurisdictions, manufacturers are seeking to improve their production outputs. Naturally, the question falls to operation and maintenance of these production centers to ensure reliable supply to market.
openaire   +1 more source

[Lutetium-177-PSMA in metastasized prostate carcinoma].

Nederlands tijdschrift voor geneeskunde, 2023
Lutetium-177 coupled with a ligand for Prostate Specific Membrane Antigen ([177Lu]Lu-PSMA) is a new treatment in The Netherlands. Patients with metastasized castration resistant prostate carcinoma and progressive disease after hormonal therapy and chemotherapy, and no other regular therapeutic options, can be referred. A good clinical performance state,
Larissa W, van Golen, Wouter, Vogel, Marnix G E H, Lam   +2 more
openaire   +2 more sources

Lutetium-177-Radioligandentherapie beim Prostatakarzinom

Uro-News, 2022
Frank Grünwald, Nicolai Mader, Nikolaos Tselis, Jennifer Wichert, Christina Nguyen Ngoc, Christian Happel, Daniel Gröner, Severine Banek, Amir Sabet   +8 more
openaire   +1 more source

Lutetium-177-PSMA-imaging-and-therapy

Reactions Weekly, 2023
  +5 more sources

Lutetium-177 dotatate

2023
Charisma DeSai, Henry Knipe, Yaïr Glick
openaire   +1 more source